Negative-Selection Enrichment of Circulating Tumor Cells from Peripheral Blood Using the Microfluidic CTC-iChip
Overview
Authors
Affiliations
The ability to isolate and analyze rare circulating tumor cells (CTCs) holds the potential to increase our understanding of cancer evolution and allows monitoring of disease and therapeutic responses through a relatively non-invasive blood-based biopsy. While many methods have been described to isolate CTCs from the blood, the vast majority rely on size-based sorting or positive selection of CTCs based on surface markers, which introduces bias into the downstream product by making assumptions about these heterogenous cells. Here we describe a negative-selection protocol for enrichment of CTCs through removal of blood components including red blood cells, platelets, and white blood cells. This procedure results in a product that is amenable to downstream single-cell analytics including RNA-Seq, ATAC-Seq and DNA methylation, droplet digital PCR (ddPCR) for tumor specific transcripts, staining and extensive image analysis, and ex vivo culture of patient-derived CTCs.
Szerenyi D, Jarvas G, Guttman A Molecules. 2025; 30(5).
PMID: 40076201 PMC: 11901967. DOI: 10.3390/molecules30050976.
Ding H, Wang J, Zhao X, Xiu S, Cai H, Ma J Oncol Lett. 2024; 28(5):545.
PMID: 39310026 PMC: 11413727. DOI: 10.3892/ol.2024.14678.
Liquid Biopsy in the Clinical Management of Cancers.
Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).
PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.